Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race

Feb 25 2019

• By Kevin Grogan

Helix — Sparks start to fly in gene therapy M&A • Source: Shutterstock

Related Content

Novartis Pharma CEO Sees Zolgensma Supplanting Spinraza

Feb 01 2019

Hemophilia Seen As Good Testing Ground For Commercializing Gene Therapy

Oct 09 2018

Roche's Hemlibra Wins Expanded FDA Approval, Opening The Door To Broad Hemophilia A Opportunity

Oct 04 2018

The First US Gene Therapy Maker Innovates On Pricing And Reimbursement

Jan 03 2018

Ablynx, Bioverativ Buys Drive Sanofi's Hematology Reign

Jan 29 2018

Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies

Nov 23 2018

Related Companies

Roche Holding AG

Spark Therapeutics, Inc.

Novartis AG

Sanofi

Sanofi

BioMarin Pharmaceutical Inc.

Sarepta Therapeutics, Inc.

Ultragenyx Pharmaceutical Inc.

PTC Therapeutics, Inc.

Solid Biosciences Inc.

Pfizer Inc.

AveXis, Inc.

Additional Topics

M & A Regenerative Medicine Commercial Deals Rare Diseases Blood & Coagulation Disorders BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window